ADMA Biologics (NASDAQ:ADMA) Shares Down 5.4% - Should You Sell?

Key Points

• ADMA Biologics' stock dropped 5.4% to $15.23, with trading volume 32% lower than its average.
• The company reported $0.15 earnings per share for its last quarter, surpassing estimates and reflecting a 13.8% revenue growth year-over-year.
• Institutional investors own 75.68% of ADMA Biologics, with significant recent increases in holdings by firms such as Invesco and State Street.

Shares of ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) dropped 5.4% during mid-day trading on Monday . The company traded as low as $15.21 and last traded at $15.23. Approximately 2,131,375 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 3,126,752 shares. The stock had previously closed at $16.11.

ADMA Biologics Price Performance

The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The business's 50-day simple moving average is $17.22 and its 200-day simple moving average is $18.93. The stock has a market cap of $3.80 billion, a PE ratio of 18.50 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. During the same quarter in the previous year, the company earned $0.13 earnings per share. ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. On average, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently bought and sold shares of ADMA. Orion Porfolio Solutions LLC lifted its stake in shares of ADMA Biologics by 70.7% in the second quarter. Orion Porfolio Solutions LLC now owns 64,587 shares of the biotechnology company's stock worth $1,176,000 after buying an additional 26,759 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of ADMA Biologics by 78.1% during the second quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company's stock valued at $60,373,000 after purchasing an additional 1,453,924 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of ADMA Biologics during the second quarter valued at approximately $404,000. Ranger Investment Management L.P. increased its holdings in ADMA Biologics by 49.1% during the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company's stock valued at $43,529,000 after buying an additional 786,865 shares during the last quarter. Finally, Cim LLC purchased a new stake in ADMA Biologics during the second quarter valued at approximately $1,654,000. Institutional investors own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.